Kaleida Capital Research
Investment Thesis
Kaleida Capital is a San Diego-based venture firm investing in what it calls "NeuroAI": brain-inspired technologies that sit at the intersection of neuroscience, artificial intelligence, and computation. The firm's stated mission is to back "pioneers of brain-inspired technologies that will enable precision medicine, enhance human abilities, and define the next era of computation." Founded in 2022 by Dr. Ariane Tom, the firm brings together deeptech operators, scientists, and policy architects to identify and back neurotechnology founders, and it explicitly frames neurotechnology broadly, beyond brain-computer interfaces, to include any system that measures, models, interfaces with, or learns from neural systems.
Sector Focus
The firm organizes its investing around four pillars:
- Precision Medicine - personalized healthcare, targeted therapies, diagnostics
- Human Performance - cognitive and physical performance, mental health enhancement
- Digital Interface - communication, productivity, and entertainment applications built on neural or brain-inspired technology
- AI and Computation - frontier AI development and next-generation computing infrastructure
Core technical domains include neural data infrastructure, brain-computer interfaces (BCI), neural engineering, neuroimaging, neurostimulation, biosensors, and deep AI applications tied to drug discovery and brain health.
Stage Focus
Publicly available sources describe Kaleida as targeting pre-seed through Series A, consistent with its role as an early, thesis-driven backer of neurotechnology founders (exact stage weighting by round was not disclosed on-site).
Check Size
Not publicly disclosed. No specific check-size range is published on the firm's website or in third-party coverage found.
Lead Tendency
Not publicly established from available sources; treated as unknown pending further evidence.
Recent Activity
Kaleida has been active in publishing its NeuroAI thesis through a steady cadence of essays authored by Dr. Tom, most recently explaining why the fund took exposure to Anthropic (obtained in 2024) as a bet on frontier AI as neural-adjacent infrastructure (published May 2026). Earlier essays cover "foundation models for the brain" (April 2026) and a broader NeuroAI market overview (January 2026). The firm's most recent notable portfolio outcome is the 2024 acquisition of Manifest Technologies, a Yale research spinout building a computational neuroimaging platform for schizophrenia and bipolar disorder drug development, documented in a case study published April 2025.
Portfolio Highlights
Kaleida's public portfolio page lists a small, concentrated set of names spanning neurotech hardware, neurotech-adjacent medical devices, and frontier AI:
- Synchron - clinical-stage endovascular brain-computer interface enabling minimally invasive neural access for communication and cognitive applications
- Paradromics - high-bandwidth BCI restoring speech and motor function for patients with paralysis, ALS, and spinal cord injuries
- Science Corporation - neurotechnology platform integrating neural interfaces and machine intelligence to restore and augment vision and cognition
- Resonant Link - wireless power transfer platform for implantable medical devices and electrified systems
- Aurenar - wearable neurostimulation device designed for rapid ICU deployment
- Manifest Technologies - computational neuroimaging platform for psychiatric drug development (acquired, 2024)
- Anthropic - frontier AI lab and developer of Claude, held as a NeuroAI infrastructure bet
- OpenAI - frontier AI lab and developer of ChatGPT
The portfolio page also displayed several additional logos without identifiable names or working links at the time of research.
Team
- Dr. Ariane Tom - Founder and Managing Director, leads NeuroAI investments across BCI, neural data, and AI-driven brain technologies
- Srihari Sritharan, PhD - Venture Fellow, has driven high-impact neurotech and biopharma deals including $100M+ and roughly $1B partnerships
- Evan Schnell, MBA - Venture Partner with 25+ years in clinical software and BCI, prior scaling experience at Synchron and Medtronic
- Kevin Carlberg, PhD - Venture Partner and former Meta AI director, focused on applied AI, wearable tech, and NeuroAI systems
The firm also maintains a nine-person Scientific Advisory Council including Tom Oxley (Synchron), Max Hodak (Science Corporation), Matt Angle (Paradromics), Sumner Norman (Merge Labs), Philip Sabes (Integral Neurotech), Sergey Stavisky (UC Davis), Justin Trotter (UC San Diego), and Edward Wood (Austin Retina Associates), reflecting deep ties into the clinical and academic neurotech ecosystem.
Decision Process
Not explicitly disclosed. The small, senior team structure (one Managing Director plus a small set of Venture Partners and a Venture Fellow) suggests a tight-knit partnership model, though this has not been confirmed by the firm directly.
Founder Preferences
Kaleida's public content and advisory network point to a strong preference for founders with deep scientific or clinical credibility in neuroscience, neural engineering, or brain-computer interfaces, often emerging from academic research (e.g., Manifest Technologies' origin as a Yale spinout) or from senior technical roles at existing neurotech and AI leaders.
Geographic Focus
Headquartered in San Diego, CA (4727 Executive Drive, Suite 300). No explicit geographic restriction was found in public materials; portfolio companies span multiple US regions.